Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies

類似資料

• Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015
  著者:: Egilman, Alexander C., 等
  出版事項: (2018)
• Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017
  著者:: Vijay, Aishwarya, 等
  出版事項: (2019)
• Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics
  著者:: Vijay, Aishwarya, 等
  出版事項: (2019)
• Prescription Drug Coverage and Spending for Medicare Beneficiaries
  著者:: Poisal, John A., 等
  出版事項: (1999)
• Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies
  著者:: Ciani, Oriana, 等
  出版事項: (2021)